200 related articles for article (PubMed ID: 25369246)
21. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway.
Cappai R; Leck SL; Tew DJ; Williamson NA; Smith DP; Galatis D; Sharples RA; Curtain CC; Ali FE; Cherny RA; Culvenor JG; Bottomley SP; Masters CL; Barnham KJ; Hill AF
FASEB J; 2005 Aug; 19(10):1377-9. PubMed ID: 15946991
[TBL] [Abstract][Full Text] [Related]
22. Secondary structural formation of alpha-synuclein amyloids as revealed by g-factor of solid-state circular dichroism.
Lin XJ; Zhang F; Xie YY; Bao WJ; He JH; Hu HY
Biopolymers; 2006 Oct; 83(3):226-32. PubMed ID: 16752390
[TBL] [Abstract][Full Text] [Related]
23. Label-free detection of early oligomerization of α-synuclein and its mutants A30P/E46K through solid-state nanopores.
Li X; Tong X; Lu W; Yu D; Diao J; Zhao Q
Nanoscale; 2019 Mar; 11(13):6480-6488. PubMed ID: 30892349
[TBL] [Abstract][Full Text] [Related]
24. The chaperone activity of α-synuclein: Utilizing deletion mutants to map its interaction with target proteins.
Rekas A; Ahn KJ; Kim J; Carver JA
Proteins; 2012 May; 80(5):1316-25. PubMed ID: 22274962
[TBL] [Abstract][Full Text] [Related]
25. Wildtype and A30P mutant alpha-synuclein form different fibril structures.
Nielsen SB; Macchi F; Raccosta S; Langkilde AE; Giehm L; Kyrsting A; Svane AS; Manno M; Christiansen G; Nielsen NC; Oddershede L; Vestergaard B; Otzen DE
PLoS One; 2013; 8(7):e67713. PubMed ID: 23861789
[TBL] [Abstract][Full Text] [Related]
26. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein.
Jo E; Fuller N; Rand RP; St George-Hyslop P; Fraser PE
J Mol Biol; 2002 Jan; 315(4):799-807. PubMed ID: 11812148
[TBL] [Abstract][Full Text] [Related]
27. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro.
Hoyer W; Cherny D; Subramaniam V; Jovin TM
Biochemistry; 2004 Dec; 43(51):16233-42. PubMed ID: 15610017
[TBL] [Abstract][Full Text] [Related]
28. Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease.
Kumar S; Sarkar A; Sundar D
Biochem Biophys Res Commun; 2009 Sep; 387(2):305-9. PubMed ID: 19580781
[TBL] [Abstract][Full Text] [Related]
29. In vitro evidence that an aqueous extract of Centella asiatica modulates α-synuclein aggregation dynamics.
Berrocal R; Vasudevaraju P; Indi SS; Sambasiva Rao KR; Rao KS
J Alzheimers Dis; 2014; 39(2):457-65. PubMed ID: 24284367
[TBL] [Abstract][Full Text] [Related]
30. Contact between the β1 and β2 Segments of α-Synuclein that Inhibits Amyloid Formation.
Shaykhalishahi H; Gauhar A; Wördehoff MM; Grüning CS; Klein AN; Bannach O; Stoldt M; Willbold D; Härd T; Hoyer W
Angew Chem Int Ed Engl; 2015 Jul; 54(30):8837-40. PubMed ID: 26119103
[TBL] [Abstract][Full Text] [Related]
31. Single-molecule FRET reveals structural heterogeneity of SDS-bound alpha-synuclein.
Veldhuis G; Segers-Nolten I; Ferlemann E; Subramaniam V
Chembiochem; 2009 Feb; 10(3):436-9. PubMed ID: 19107759
[TBL] [Abstract][Full Text] [Related]
32. Assays for α-synuclein aggregation.
Giehm L; Lorenzen N; Otzen DE
Methods; 2011 Mar; 53(3):295-305. PubMed ID: 21163351
[TBL] [Abstract][Full Text] [Related]
33. Alpha-synuclein multistate folding thermodynamics: implications for protein misfolding and aggregation.
Ferreon AC; Deniz AA
Biochemistry; 2007 Apr; 46(15):4499-509. PubMed ID: 17378587
[TBL] [Abstract][Full Text] [Related]
34. Familial Parkinson disease-associated mutations alter the site-specific microenvironment and dynamics of α-synuclein.
Sahay S; Ghosh D; Dwivedi S; Anoop A; Mohite GM; Kombrabail M; Krishnamoorthy G; Maji SK
J Biol Chem; 2015 Mar; 290(12):7804-22. PubMed ID: 25635052
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Kinetics, Toxicity, Oligomer Formation, and Membrane Binding Capacity of α-Synuclein Familial Mutations at the A53 Site, Including the Newly Discovered A53V Mutation.
Mohite GM; Kumar R; Panigrahi R; Navalkar A; Singh N; Datta D; Mehra S; Ray S; Gadhe LG; Das S; Singh N; Chatterjee D; Kumar A; Maji SK
Biochemistry; 2018 Sep; 57(35):5183-5187. PubMed ID: 29771508
[TBL] [Abstract][Full Text] [Related]
36. Investigation of α-Synuclein Amyloid Fibrils Using the Fluorescent Probe Thioflavin T.
Sulatskaya AI; Rodina NP; Sulatsky MI; Povarova OI; Antifeeva IA; Kuznetsova IM; Turoverov KK
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142878
[TBL] [Abstract][Full Text] [Related]
37. Phase transitions and structure analysis in wild-type, A30P, E46K, and A53T mutants of α-synuclein.
Healey MA; Woodside MT; Tuszynski JA
Eur Biophys J; 2016 May; 45(4):355-64. PubMed ID: 26695014
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of membrane interaction and disruption by α-synuclein.
Reynolds NP; Soragni A; Rabe M; Verdes D; Liverani E; Handschin S; Riek R; Seeger S
J Am Chem Soc; 2011 Dec; 133(48):19366-75. PubMed ID: 21978222
[TBL] [Abstract][Full Text] [Related]
39. Structure and topology of the non-amyloid-beta component fragment of human alpha-synuclein bound to micelles: implications for the aggregation process.
Bisaglia M; Trolio A; Bellanda M; Bergantino E; Bubacco L; Mammi S
Protein Sci; 2006 Jun; 15(6):1408-16. PubMed ID: 16731975
[TBL] [Abstract][Full Text] [Related]
40. Distinct higher-order α-synuclein oligomers induce intracellular aggregation.
Illes-Toth E; Ramos MR; Cappai R; Dalton C; Smith DP
Biochem J; 2015 Jun; 468(3):485-93. PubMed ID: 25851527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
